Abbott’s stent sales halt shows physicians didn’t buy into the next new, shiny object
Abbott touted its Absorb fully-resorbable coronary scaffold but physicians never saw clear clinical benefit over the standard of treatment leading the company to halt sales of the expensive device just over a year after FDA approval.